Quince Therapeutics Announces President to Depart Sept. 8, 2026

What Happened

• Quince Therapeutics, Inc. filed an 8-K (Item 5.02) disclosing that President Charles Ryan and the company agreed his last day of employment will be September 8, 2026. The decision was determined on August 23, 2026 and the report was filed on August 27, 2026.
• The filing states Mr. Ryan will be eligible for certain severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023; the applicable terms are described in the company’s definitive proxy (Schedule 14A) filed August 25, 2026.

Key Details

• Officer: Charles Ryan, President of Quince Therapeutics.
• Effective last day: September 8, 2026 (decision made August 23, 2026).
• Severance: Eligibility for benefits under the Executive Change in Control and Severance Agreement (dated Sept. 1, 2023); specifics referenced in the Aug. 25, 2026 proxy filing.
• Report type: Form 8-K, Item 5.02 — departure of a senior officer.

Why It Matters

• Leadership change: Departure of the company’s President may affect operational leadership and strategic continuity until a replacement or interim structure is announced.
• Compensation impact: Potential severance payments are contractually defined and disclosed in the proxy; these could affect near-term cash outflows or reported compensation expense.
• What investors should do: Review the referenced Schedule 14A section “Executive Compensation—Potential Payments Upon Termination or Change of Control” for details on severance terms, and watch for additional company disclosures about succession plans or interim leadership.